Biology & Medicine


Researchers at NDSU have developed novel compounds that selectively induce apoptosis in tumor cells while sparing normal cells

Researchers at NDSU have developed an antimicrobial water-based rinse that contains active amounts of acetoacetate (AAA) and ethyl acetoacetate (EAA), which can be used to reduce microbial contamination on many surfaces.

Scientists at NDSU have developed a novel technique and device to quantify and detect low abundance biomolecules in patient samples. This technique is useful in point-of-care, cancer screening settings. The apparatus itself is compact and compatible with available imaging technologies.

Scientists at NDSU have developed a method to rapidly produce safe and efficacious vaccines against emerging RNA viruses. This is accomplished by damaging or destroying the RNA genome (so replication is diminished or eliminated) while maintaining the structural integrity of the capsid so antibodies recognize the native virus.
Scientists at NDSU have developed a small device for improved CAR T cell production, which speeds the turnaround time by enabling CAR T cell production 'on-site' at a hospital or cancer clinic. This simple, microfluidic device is easy to make and use, with an automated transfection process that takes about one hour. 

Scientists at NDSU have developed a flexible, modular, bone scaffold for filling large bone gaps and accelerating bone growth with various additives, such as nutrients, cytokines, therapeutics, and minerals incorporated into the scaffold. The scaffold is made of clay and a polymer.

Scientists at North Dakota State University have developed an anti-cancer compound that indirectly targets the over-expression of COX-2, with the potential to treat multiple cancer types.
NDSU Scientists have developed a liposome-based delivery method with the potential to reduce chemotherapy side effects while maintaining or even increasing cancer drug efficacy. The liposome is stabilized in the bloodstream using polyethylene glycol (PEG) and remains stable in the vicinity of healthy cells. However, upon arrival at a tumor, the liposome rapidly disintegrates, releasing its contents to be taken up by tumor cells. This disintegration is triggered by conditions found in the tumor extracellular matrix (ECM), specifically the reducing conditions and the presence of Matrix Metalloproteinase 9 (MMP-9). As a result, these liposomes can carry drugs and imaging agents to tumors, releasing them so that a high concentration is available for rapid uptake into tumor cells, and reducing the amount of time these agents spend in the circulatory system or in the vicinity of healthy cells. A reduction in tumor growth was observed using this technology to deliver drugs in a mouse model of pancreatic cancer. 
Scientists at NDSU have developed a monoclonal antibody that inhibits activation of the receptor for advanced glycation end products (RAGE). The antibody binds the V-domain to block the activation of RAGE by its ligands. This domain is capable of binding to multiple structurally and functionally diverse ligands, all of which trigger signal transduction by RAGEs cytosolic domain, and results in sustained inflammation that is associated with diabetes, cancers, Alzheimer's, multiple sclerosis, and other diseases associated with chronic inflammation. As a result, the anti-RAGE monoclonal antibodies have the potential to treat a wide variety of diseases. 

This technology is a monoclonal antibody recognizing the V domain of the receptor for advanced glycation endproducts (RAGE). RAGE is emerging as a biomarker in many human diseases such as diabetes, cancer, and Alzheimer's disease. In animal models, antibodies against RAGE have been shown to reduce RAGE deleterious signaling. RAGE is a cell-surface receptor that is activated by several ligands. RAGE is therefore a suitable target for monoclonal antibodies. We have generated monoclonal antibodies with the aim of blocking RAGE/ligand interaction and decreasing RAGE deleterious effects in several human diseases
NDSU engineers have developed an improved design and material for Total Ankle Replacements (TARs) that features an inverted design, in which the concave portion of the joint is on the bottom and the convex on the top. This inverted design and the mode of assembly and implantation offer several benefits to surgeons and patients. 

Scientists at North Dakota State University have developed a method to confer dual-action and broad-spectrum (gram +, gram -, and yeast) anti-microbial properties into polymers and coatings. The anti-microbial components are quaternary ammonium salts (QAS) and silver. The QAS component is attached to the polysiloxane backbone. It may be strongly attached to provide a contact-active anti-microbial or may be gradually released and leachable. Silver may also be integrated, and the NDSU technology enables silver to be efficiently incorporated just into the outer portion of a surface by dipping into an appropriate silver solution. This means the silver need not be included throughout a polymer or coating layer but instead can be positioned right at the surface where essentially all the silver is available and provides a rapid anti-microbial effect once the surface is hydrated. The resulting materials include both a rapidly acting soluble anti-microbial component and a longer-lasting contact-active component to kill microbes that make direct contact with the material.